Episode 61: Woody Bryan, President and CEO of Revolo Biotherapeutics

Why is a feather-light touch important in fighting infections?
Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chr...

Episode 60: Part Two: Yochi Slonim, Co-Founder and CEO at Anima Biotech

Can AI see and talk to human cells? Find out in today's episode of the Biorasi Few & Far Between podcast.
Host Chris O'Brien welcomes Yochi Slon...

Episode 59, Part One: Yochi Slonim, Co-Founder and CEO at Anima Biotech

What do software bugs and human cells have in common? Find out in today's episode of the Biorasi Few & Far Between podcast.
Host Chris O'Brien w...

Episode 58: Jerry McLaughlin, CEO and Board Member at Life Biosciences

How does a biopharma background prepare you for the biotech playground?
Find out in our latest episode of the Biorasi Few & Far Between podcast!...

Episode 57: Jim Brown, DVM, President and CEO of DURECT Corporation

Is the epigenome the "software" of the cell nucleus?
Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien...

Episode 56, Part Two: Michael Tolentino, MD, Co-Founder and Head Scientific Consultant, Aviceda Therapeutics

How do experienced troubleshooters solve a difficult problem? By asking the right questions first!
Welcome back to part two of our conversation...

Episode 55: Julio G. Martinez-Clark, CEO and Co-Founder at bioaccess®

How much do you know about clinical trials in Latin America? Take a deep dive with us as we explore the benefits and risks of running studies in this...

Episode 54, Part One: Michael Tolentino, MD, Co-Founder and Head Scientific Consultant, Aviceda Therapeutics

The challenge? Decoding the human immune system. Get ready to meet the top challenger on today's episode of the Biorasi Few & Far Between podcast.

Episode 53: Frank David, Founder and Managing Director, Pharmagellan

How do mission, vision, and data analysis fit into today's biotech goals?
Host Chris O'Brien welcomes Frank David, Founder and Managing Director...

Episode 52: Joshua Kresh, Emily Michiko Morris, and Mark Schultz, IPPI

How does a biotech balance great science with IP security to tell their story? Find out on today's episode of the Few & Far Between podcast!
Hos...

Episode 51: Dan Oliver, CEO and Founder, Rejuvenate Bio

How do you turn back the epigenetic clock for humans and their animal companions? 
Host Chris O'Brien welcomes Dan Oliver, CEO and Founder of Re...

Epsiode 50: Jonathan Rigby, Chairman and CEO, Sernova

Now on the Few & Far Between podcast:
Did you know that one in ten people with Type 1 Diabetes (TD1) die from hypoglycemia? Today's guest, who h...

Episode 49: Eileen Faucher, Principal and Founder, Brass Tacks Health

Today on the Biorasi Few & Far Between podcast:
What if you could read a story before its official release? Competitive intelligence gives you e...

Episode 48: John Celebi, President and CEO, Sensei Bio

"You have to have the right people, the right team, and good science." - John Celebi, President and CEO, Sensei Bio
Welcome back to Biorasi's Fe...

Episode 46: Ben Olds and Amy Fenollosa, Haven Human Asset Ventures

"There's that old saying, 'culture is how people behave when nobody's looking.' So, if you want to be effective, your [mission and value statements] h...

Episode 47 - Marc Lajoie, CEO at Outpace Bio

"If you bring powerful technology to a problem that is well understood, then you can really make a difference." - Marc Lajoie, CEO at Outpace Bio

Episode 46: Dr. Carsten Rudolph, CEO and Managing Director at Ethris

"It's really a very important challenge we had from the very beginning, to see how to stabilize nanoparticles with the messenger RNA so they are not d...

Episode 44: Jonathan Scheiman, PhD, Co-Founder and CEO at FitBiomics

"We don't endeavor to make elite athletes better. We endeavor to make society healthier." - Jonathan Scheiman, PhD, Co-Founder and CEO at FitBiomics

Episode 43: Isaac Stoner, Co-founder and CEO at Octagon Therapeutics

"I hope we're moving into the age of the generalist, where knowing how to learn and learning how to learn are more important than specialized knowledg...

Episode 42: Diana Azzam, PhD, Assistant Professor at Florida International University, Co-Founder at First Ascent Biomedical

“Our studies are open for those that have exhausted standard of care, and we're showing improved responses, and the data is promising. So, I really ho...

Episode 41: Craig Serra, Head of Clinical Research Scientific and Technical Engagement, Flatiron Health

"It's amazing how many companies there are and how many opportunities for a kind of a match between a human that needs some help and a company that ca...

Episode 40: Professor Justin Stebbing, Editor-in-Chief, Oncogene journal

"I learned very early on that the stupidest cancer cell was cleverer than the cleverest oncologist." - Justin Stebbing, Editor-in-Chief of Oncogene, p...

Episode 39: Dr. Keith Flaherty, Director of Clinical Research at Massachusetts General Hospital Cancer Center

"Technologies have changed enormously in terms of how we can basically procure, preserve, and then interrogate a tumor specimen...like effectively in...

Episode 38: Dr. Ole Isacson, Professor of Neurology and Neuroscience, Harvard Medical School

"Artificial Intelligence is a tool that really levels up and creates almost like an equity for everybody to participate and, when used effectively, to...

Episode 37: Will Greene, Prader-Willi Syndrome patient advocate, Healthcare Engagement Lead at Roche

"The history of rare disease drug development indicates that once you start looking harder for cases, you often tend to find them." - Will Greene, Pra...

Episode 36: Zak Kohane, Department of Biomedical Informatics at Harvard Medical School

"Patients have already been exposed to these large language models (LLMs). Yes, they are aware of the risks, but they are also very aware of the benef...

Episode 35: Charlene Son Rigby, CEO at Global Genes

"And what I was really surprised about was that everybody was doing data collection in a different way. And I kept thinking that, gosh, there's a lot...

Episode 34: Dan Mandell, CEO at GRO Biosciences

"So we built the seatbelts before the car, so to speak, wherein we did a project to figure out ways to biocontain these organisms. And the strategy th...

Episode 33: Diana Sims-Silbermann, Clinician and Former Senior Trial Manager at Janssen Pharmaceuticals

Episode 32: Stephanie Wisner, Author, Co-Founder at Centivax

"In research or in biotech, time is expensive. Time is the most expensive thing that you have." - Stephanie Wisner, Author, Co-Founder at Centivax

Episode 31: Pam Cusick, SVP, Rare Patient Voice

"What can I contribute that my doctor can't contribute? And that's a real 'a-ha' moment when we share with them how they're the experts in their condi...

Episode 30, Part Two: Dr. Francisco Harrison, CEO and owner, Harrison CST Holding GmbH

"We have to rethink the sense of clinical research from the point of view that if we have the possibility to have markers that indicate that there may...

Episode 30, Part One: Dr. Francisco Harrison, CEO and owner, Harrison CST Holding GmbH

"I love clinical research. I will spend my life in clinical research." Dr. Francisco Harrison, CEO and owner, Harrison CST Holding GmbH
Biorasi...

Episode 29: Mika Newton, CEO at XCures

"We work with hundreds of patients a month, helping them understand their own medical history and then tracking what happens to them in the future and...

Episode 28: Dr. Alok Tayi, Founder and CEO of VibeBio

“I think one of the key insights and observations you make when you have a child who's sick and you spend time with other families who have sick kids...

Episode 27, Part 2: Jamie Heywood, Biotech Engineer and Entrepreneur

"Humans have the right to study themselves." - Jamie Heywood, CEO at Alden Scientific
Welcome back to Part 2 of our special Few & Far Between po...